JTJulia Axiina Tuominen

Julia Axiina Tuominen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julia Axiina Tuominen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of Medication Use and 8-Year Mortality Risk in Patients With Parkinson Disease

    by Julia A. Tuominen, Trond Riise, Julia Romanowska, Mario H. Flores-Torres, Marianna Cortese, Clemens R. Scherzer, Kjetil Bjornevik, Jannicke Igland

    There are currently no treatments that can halt or slow the progression of Parkinson disease (PD). The aim of this study was to identify new drug repurposing candidates for PD among existing prescription drugs that could be used to modify the disease course. This nationwide observational cohort study (2004-2020) used Norwegian health registries and was conducted as a high-throughput drug screen using an emulated target trial design. All individuals who met our prescription-based classification criteria for PD, were older than 25 years at the time of diagnosis, and were not prescribed the target drug in the past 2 years were included. We emulated a target trial for any drug filled by a minimum of 100 individuals at any pharmacy in Norway, which amounted to a total of 219 drugs. Mortality was used as an outcome to indicate disease progression. We estimated the effect of drug initiation, an observational analog of the intention-to-treat effect, on the 8-year risk of death, comparing initiators of the target drug with initiators of drugs within the same Anatomical Therapeutic Chemical classification system level 1 group. Inverse probability of treatment weighting was used to adjust for potential confounders. The study included 14,289 individuals with PD (mean age 72 at diagnosis, 59% male) and identified 23 drugs associated with reduced mortality risk at 8 years. These drugs included ranitidine (histamine-2 blocker); pantoprazole and esomeprazole (proton pump inhibitors); losartan (angiotensin receptor blocker); atorvastatin (for high cholesterol); tadalafil (for erectile dysfunction); levothyroxine sodium (thyroid hormone); phenoxymethylpenicillin, erythromycin, and azithromycin (antibiotics); 4 nonsteroidal anti-inflammatory drugs; combined codeine/paracetamol and tramadol (opioid analgesics); zopiclone and melatonin (sleep aids); mianserin (antidepressant); mometasone (nasal corticosteroid); 2 opium-derived cough medicines; and dexamethasone (ophthalmologic corticosteroid). Our study identified several drugs with potential disease-modifying properties that could be candidates for future clinical trials. It highlights the potential of repurposing existing medications to advance drug development. While these findings are exploratory and, therefore, insufficient to justify immediate clinical application, they warrant further investigation and potential inclusion in clinical trials.


  • Open Access

    Association Between Use of Any of the Drugs Prescribed in Norway and the Subsequent Risk of Parkinson Disease

    by Julia Romanowska, Kjetil Bjornevik, Marianna Cortese, Julia A. Tuominen, Magne Solheim, Asieh Abolpour Mofrad, Jannicke Igland, Clemens R. Scherzer, Trond Riise

    Background and objectives: The incidence rate of Parkinson’s disease (PD) has been increasing rapidly during the last years. Yet, no treatments exist to prevent or slow the progression of the disease. Moreover, we are unable to detect early disease stages during which intervention with disease-modifying therapies is most likely to succeed. The objective of this study was to perform an agnostic drug-wide association study (DWAS) estimating the association between use of any of the drugs prescribed in Norway and the subsequent risk of PD. Methods: This registry-based cohort study use data from the entire Norwegian population between 2004–2019 linked to the Norwegian Prescription Registry, with more than 600 million individual prescriptions. Drug classes were screened according to ATC codes at level 2, corresponding to therapeutic subgroups. We used Cox regression models to estimate hazard ratios (HRs) and 95% confidence intervals (95% CI) for the associations between drug classes and PD risk. All p-values were corrected for multiple testing using the false discovery rate. Additionally, we conducted sensitivity analyses of exposure definition, as well as time-lag and dose-response analyses. Results: The study population comprised 3,223,672 individuals, 15,849 of whom developed PD during the follow-up. We identified thirty-one drug classes that were statistically significantly associated with PD risk in Norway during the follow-up. Drugs acting on the renin-angiotensin system (HR = 0.92, 95% CI: 0.89–0.95), corticosteroids for systemic use (0.88, 95% CI: 0.84–0.93), and vaccines (0.89, 95% CI: 0.82–0.96) were associated with a decreased risk of PD even up to 10 years prior to PD onset. Drug classes used to treat symptoms related to prodromal signs of PD such as constipation, urological issues, and depression were associated with an increased risk of subsequent diagnosis of PD with HRs of 1.6 (95% CI: 1.49–1.73), 1.48 (1.42–1.53), and 1.94 (1.87–2.01), respectively. Discussion: This drug-wide study identified thirty-one drug classes that were associated with the PD risk change. It reveals links of renin-angiotensin system medications, vaccines, and corticosteroids with PD risk and suggests that monitoring drug usage using pharmacoepidemiology may allow identifying individuals with prodromal PD.


  • Open Access

    An information-theoretic analysis of resting-state versus task fMRI

    by Julia Tuominen, Karsten Specht, Liucija Vaisvilaite, Peter Zeidman

    Resting-state fMRI is an increasingly popular alternative to task-based fMRI. However, a formal quantification of the amount of information provided by resting-state fMRI as opposed to active task conditions about neural responses is lacking. We conducted a systematic comparison of the quality of inferences derived from a resting-state and a task fMRI paradigm by means of Bayesian Data Comparison. In this framework, data quality is formally quantified in information-theoretic terms as the precision and amount of information provided by the data on the parameters of interest. Parameters of effective connectivity, estimated from the cross-spectral densities of resting-state- and task time series by means of dynamic causal modelling (DCM), were subjected to the analysis. Data from 50 individuals undergoing resting-state and a Theory-of-Mind task were compared, both datasets provided by the Human Connectome Project. A threshold of very strong evidence was reached in favour of the Theory-of-Mind task (>10 bits or natural units) regarding information gain, which could be attributed to the active task condition eliciting stronger effective connectivity. Extending these analyses to other tasks and cognitive systems will reveal whether the superior informative value of task-based fMRI observed here is case specific or a more general trend.


  • Open Access

    Beta2-adrenoreceptor agonists and long-term risk of Parkinson's disease

    by Julia A. Tuominen, Kjetil Bjørnevik, Julia Romanowska, Magne H. Solheim, Thomas B. Grydeland, Marianna Cortese, Clemens R. Scherzer, Trond Riise, Jannicke Igland


  • Open Access

    An Information-Theoretic Analysis of Resting-State versus Task fMRI

    by Julia Axiina Tuominen, Karsten Specht, Liucija Vaisvilaite, Peter Zeidman

    Similarities in brain functional connectivity under various imaging conditions have led to resting-state fMRI becoming the preferred alternative to task-based fMRI in many experimental and clinical contexts. However, the equal or superior quality of the data obtained from resting-state fMRI for inferring neural responses is yet to be demonstrated. Here, a systematic comparison of the quality of inferences derived from both imaging paradigms was conducted by means of Bayesian Data Comparison. In this framework, data quality is formally quantified in information theoretic terms as the precision and amount of information provided by the data on the parameters of interest. Parameters of effective connectivity models, estimated from the cross-spectral densities of resting-state- and task time series by means of Dynamic Causal Modelling, were subjected to the analysis. Data from 50 individuals undergoing a Theory-of-Mind task were compared to data from the same individuals undergoing resting-state, both datasets provided by the Human Connectome Project. The examined network was specified from an independent component extracted from the resting-state data and the specific component was selected based on its overlap with the Theory-of-Mind activation map. A threshold of very strong evidence was reached in favour of the Theory-of-Mind condition regarding information gain over connectivity parameters. No notable differences were observed in parameter precision. The active task elicited stronger effective connectivity in this specific network and should be preferred over resting-state in settings where the detectability of the network is crucial, such as in clinical applications.